5 quarters tracked · Beat rate 20% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.29 | $1.31 | +1.4% | Beat |
| Q1 2026 | 2026-03-31 | $1.16 | $1.15 | -0.5% | Miss |
| Q4 2025 | 2025-12-31 | $1.51 | $1.50 | -0.7% | Miss |
| Q3 2025 | 2025-09-30 | $1.31 | $1.30 | -1.1% | Miss |
| Q2 2025 | 2025-06-30 | $1.27 | $1.26 | -0.6% | Miss |
Earnings Beat Rate
Abbott Laboratories has beaten analyst EPS estimates in 1 of 5 tracked quarters (20% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →